NasdaqGM:OCULPharmaceuticals
Ocular Therapeutix (OCUL): Assessing Valuation After FDA Agreement Unlocks Clear Path for Key Pipeline Asset
Ocular Therapeutix (OCUL) just gave investors something fresh to consider, announcing it has secured a written agreement with the FDA on how it will design a pivotal clinical trial for AXPAXLI (OTX-TKI) in non-proliferative diabetic retinopathy. This is more than just a routine update; it represents a milestone that clears the way for one of the company’s key pipeline assets in a field still seeking improved solutions. For investors wondering if this is the signal they’ve been waiting for,...